# High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes

> **NCT03403556** · PHASE4 · UNKNOWN · sponsor: **Yuhan Corporation** · enrollment: 140 (estimated)

## Conditions studied

- Atherosclerotic Cardiovascular Disease
- Type 2 Diabetes

## Interventions

- **DRUG:** Rosuvamibe
- **DRUG:** Monorova

## Key facts

- **NCT ID:** NCT03403556
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-27
- **Primary completion:** 2021-10
- **Final completion:** 2021-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2020-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403556, "High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03403556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*